A5036587861- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Cancer therapeutics and mechanisms
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Glycosylation and Glycoproteins Research
- RNA modifications and cancer
- Pancreatic and Hepatic Oncology Research
- Cancer, Hypoxia, and Metabolism
- Neuroblastoma Research and Treatments
- Angiogenesis and VEGF in Cancer
- Gastric Cancer Management and Outcomes
- Lymphoma Diagnosis and Treatment
- Statistical Methods in Clinical Trials
- Radiomics and Machine Learning in Medical Imaging
- Ubiquitin and proteasome pathways
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- Occupational and environmental lung diseases
University Hospitals Seidman Cancer Center
2016-2025
Case Western Reserve University
2016-2025
Case Comprehensive Cancer Center
2008-2024
University Hospitals Cleveland Medical Center
2015-2024
University Hospitals of Cleveland
2015-2024
University School
2003-2024
Sarah Cannon
2004-2024
Tennessee Oncology
2005-2024
Western University
2014-2024
Palmetto Hematology Oncology
2016-2023
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with variety of cancers.Between July 2001 and April 2004, the Eastern Cooperative Oncology Group (ECOG) conducted randomized study in which 878 recurrent or advanced non-small-cell lung cancer (stage IIIB IV) were assigned chemotherapy paclitaxel carboplatin alone (444) plus bevacizumab (434). Chemotherapy was administered every 3 weeks for six cycles, until disease progression...
Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers children and adults. We evaluated the efficacy safety larotrectinib, a highly selective TRK inhibitor, adults who had tumors with these fusions.We enrolled patients consecutively prospectively identified fusion-positive cancers, detected by molecular profiling as routinely performed at each site, into protocols: phase 1 study adults, 1-2 children, or 2 adolescents The primary end point for combined...
Abbreviations used in this article: DRG, Diagnostic Related Group; DVT, deep vein thrombosis; HCFA, Health Care Financing Administration; ICD-9, International Classification of Diseases, 9th Revision; MEDPAR, Medicare Provider Analysis and Review Record; PE, pulmonary embolism.
This study (EGF10004) assessed the safety/tolerability, pharmacokinetics, and clinical activity of daily oral dosing with lapatinib (GW572016) in patients ErbB1-expressing and/or ErbB2-overexpressing advanced-stage refractory solid tumors.Heavily pretreated metastatic cancers were randomly assigned to one five dose cohorts administered once daily. Pharmacokinetic samples obtained on days 1 20. Clinical response was every 8 weeks.Sixty-seven tumors treated lapatinib. The most frequently...
Targeting DLL3 with an antibody-drug conjugate eliminates tumor-initiating cells in high-grade pulmonary neuroendocrine cancers.
Abstract Purpose: The safety, pharmacokinetics, and clinical activity of pazopanib (GW786034), an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-derived c-Kit, were evaluated in patients with advanced-stage refractory solid tumors. Experimental Design: Patients enrolled into sequential dose-escalating cohorts (50 mg three times weekly to 2,000 once daily 300-400 twice daily). Escalation or deescalation was based on toxicities observed the...
This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients with advanced ErbB1 and/or ErbB2-overexpressing solid malignancies.Heavily pretreated metastatic cancers overexpressing ErbB2 expressing were randomly assigned one five dose cohorts (GW572016) administered orally once daily continuously. The growth and survival assessed biopsies obtained before after 21 days therapy. Clinical response determined at 8 weeks.Sequential from...
LBA4 Background: The results of a randomized phase II trial PC +/- bevacizumab (A) suggested improved activity for the combination PCA when compared to alone (Johnson DH, et al JCO 2004). Grade 5 hemoptysis was seen in arms & multivariate analysis squamous cell histology be significant risk factor. Methods: primary endpoint this compare effects addition A on overall survival patients (pts) with previously untreated non-squamous NSCLC. Secondary endpoints included response rate, time...
Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients Methods A total 104 patients with recurrent SCLC were randomly assigned 1:1 oral or placebo 40 mg twice daily, days 1 7, 150 200 mg/m
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management patients with SCLC, including diagnosis, primary treatment, surveillance relapse, and subsequent treatment. This selection the journal focuses on metastatic (known as extensive-stage) which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms prolong survival most extensive-stage disease. Smoking cessation counseling intervention...
Abstract Purpose: Although extensive-stage small-cell lung cancer (SCLC) is highly responsive to first-line therapy, virtually all patients develop resistance with short survival. Rovalpituzumab tesirine (Rova-T) an antibody–drug conjugate targeting delta-like 3 protein (DLL3). This open-label, single-arm, phase II study (TRINITY) assessed safety and efficacy of Rova-T in DLL3-expressing SCLC the third-line beyond (3L+) setting. Patients Methods: (determined by mouse antibody...
The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease management. These Insights focus on recent updates to the SCLC regarding immunotherapy, systemic therapy, and radiation therapy. For 2018 update, new sections were added “Signs Symptoms SCLC” “Principles Pathologic Review.”
<h3>Importance</h3> Patients with malignant mesothelioma whose disease has progressed after platinum and pemetrexed treatment have limited options. Anti–programmed cell death 1 (PD-1) antibodies antitumor activity in this disease, but little is known about the of anti–programmed ligand (PD-L1) patients mesothelioma. <h3>Objective</h3> To assess efficacy safety avelumab a cohort previously treated <h3>Design, Setting, Participants</h3> Phase 1b open-label study (JAVELIN Solid Tumor)...
PURPOSE Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatments. Delta-like ligand 3 (DLL3) aberrantly expressed in most SCLC. Tarlatamab (AMG 757), a bispecific T-cell engager molecule, binds both DLL3 and CD3 leading to T-cellb–mediated tumor lysis. Herein, we report phase I results of tarlatamab patients PATIENTS AND METHODS This study evaluated relapsed/refractory The primary end point was safety. Secondary points included antitumor activity by modified RECIST...
Abstract Small cell lung cancer (SCLC) is a recalcitrant neuroendocrine carcinoma with dismal survival outcomes. A major barrier in the field has been relative paucity of human tumors studied. Here we provide an integrated analysis 3,600 “real-world” SCLC cases. This large cohort allowed us to identify new recurrent alterations and genetic subtypes, including STK11-mutant (1.7%) TP53/RB1 wild-type (5.5%), as well rare cases that were papillomavirus–positive. In our cohort, gene...
Abstract Background: E4599 was a phase II/phase III trial, in which 878 patients with advanced non–small cell lung cancer were randomized to carboplatin + paclitaxel (PC arm) or PC bevacizumab (BPC arm). Survival and progression-free survival superior on the BPC arm. The rationale for markers used this correlative study based elevated vascular endothelial growth factor (VEGF), basic fibroblast (bFGF), soluble intercellular adhesion molecule (ICAM) E-selectin variety of malignances changes...
Agents inhibiting the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin (PAM) pathway are currently in various stages clinical development oncology, ranging from some early-phase evaluations to others that have already received regulatory approval for treatment advanced cancers. The administration PAM inhibitors has been associated with metabolic toxicities hyperlipidemia and hyperglycemia. Task Force National Cancer Institute Investigational Drug Steering Committee convened an...
Anaplastic thyroid cancer (ATC) is a rare but highly aggressive malignancy with median survival of 3-5 months. The BRAF oncogene mutated to its active form in up 24% ATC cases. Sorafenib tyrosine kinase inhibitor that acts on the RAF-1 serine/threonine kinase. In preclinical mouse models, sorafenib inhibits growth xenografts and improves survival. No study has been conducted. We conducted multi-institutional phase II trial patients who had failed two previous therapies.The primary endpoint...
Current noninvasive imaging methods are not sufficiently reliable for accurate detection of malignancy in most solitary pulmonary nodules (SPNs). Positron emission tomography (PET) using 18-fluorodeoxyglucose (FDG), showing increased FDG uptake and retention malignant cells, has proved useful to differentiate from benign tissue could, therefore, contribute the evaluation SPN. We performed a prospective study 50 patients referred Pneumology Department with unclear diagnoses SPN after...